Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | VNN1 | O95497 | 3/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18525794 | 0.90 | KDM5A (0.59) | KDM5AKDM4CKDM5BMRGPRX4MAPK14 | |
| SCHEMBL18526087 | 0.88 | MAPK14 (0.53) | KDM5AKDM4CKDM5BMAPK14ROCK2 | |
| SCHEMBL18525810 | 0.87 | HDAC1 (0.48) | KDM5AKDM4CKDM5BMRGPRX4MAPK14 | |
| SCHEMBL18526082 | 0.84 | HDAC1 (0.49) | KDM5AKDM4CKDM5BMAPK14ROCK2 | |
| SCHEMBL18526203 | 0.84 | ROCK2 (0.56) | KDM5AKDM4CKDM5BMRGPRX4MAPK14 | |
| SCHEMBL22102122 | 0.82 | KDM5A (0.49) | KDM5AKDM4CKDM5BMAPK14ROCK2 | |
| SCHEMBL18511956 | 0.82 | GABRA5 (0.55) | VNN1GABRA5 | |
| SCHEMBL18525813 | 0.82 | APP (0.49) | KDM5AKDM4CKDM5BMRGPRX4ROCK2 | |
| SCHEMBL18525796 | 0.82 | DGAT1 (0.51) | ROCK2ROCK1L3MBTL1SCD | |
| SCHEMBL18525811 | 0.82 | APP (0.49) | KDM5AKDM4CKDM5BMRGPRX4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | KDM5A 1424/4885KDM4C 2216/4885KDM5B 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.